SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will initiate an offering of 4,000,000 shares of common stock pursuant to an automatically effective shelf registration statement on file with the Securities And Exchange Commission. It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 600,000 shares.
Credit Suisse Securities (USA) LLC will be acting as the sole book-runner for the offering, with Thomas Weisel Partners LLC, Jefferies & Company, Inc. and Oppenheimer & Co. Inc. acting as co-managers.
A preliminary prospectus supplement relating to these securities will be filed with the Securities and Exchange Commission but remains subject to completion. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the prospectus supplement and related prospectus are delivered in final form. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities.
Copies of the preliminary prospectus supplement and related prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Prospectus Department, One Madison Avenue, New York, New York 10010-3629 (Telephone number 1-800-221-1037).
About Rigel (http://www.rigel.com)
We are a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to file one new investigative new drug application in a significant indication each year. We have achieved this goal each year beginning in 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Our productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and thrombocytopenia, and cancer, as well as partnered product development programs relating to asthma and cancer.
This press release contains "forward-looking" statements, including
statements related to Rigel's plans to complete a public offering and its
strategy to further develop a portfolio of product candidates. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such
as "plans," "intends," "promising," "expects," "anticipates" and similar
expressions are intended to identify these forward-looking statements.
There are a number of important factors that could cause Rigel's results to
differ materially from those indicated by these forward-looking statements,
including risks associated with the timing and success of preclinical and
clinical trials, as well as other risks detailed from time to time in
Rigel's SEC reports, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2007. Rigel does not undertake any obligation
to update forward-looking statements.
Contact: Ryan Maynard
Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
|SOURCE Rigel Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved